TGA commences evaluation of Moderna COVID-19 vaccine (Spikevax) for potential transition to full registration

TGA

20 January 2023 - The TGA has commenced evaluation of an application from Moderna to transition its COVID-19 vaccine, Spikevax, to full registration for the immunisation of individuals 6 years and over, and as a booster dose for individuals aged 12 years and older.

This is the first application received by the TGA to transition a provisionally approved COVID-19 vaccine to full registration. 

Read TGA press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Regulation , Australia , Vaccine , Dossier